These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33312365)

  • 1. Adoptive CD8
    Fu J; Yu A; Tang J; He B; Chen W
    Am J Transl Res; 2020; 12(11):7262-7274. PubMed ID: 33312365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.
    Contreras A; Beems MV; Tatar AJ; Sen S; Srinand P; Suresh M; Luther TK; Cho CS
    J Immunother Cancer; 2018 May; 6(1):41. PubMed ID: 29843822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.
    He H; Wisner P; Yang G; Hu HM; Haley D; Miller W; O'Hara A; Alvord WG; Clegg CH; Fox BA; Urba WJ; Walker EB
    J Transl Med; 2006 Jun; 4():24. PubMed ID: 16772043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
    Ng SSM; Nagy BA; Jensen SM; Hu X; Alicea C; Fox BA; Felber BK; Bergamaschi C; Pavlakis GN
    Clin Cancer Res; 2017 Jun; 23(11):2817-2830. PubMed ID: 27986749
    [No Abstract]   [Full Text] [Related]  

  • 6. Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory.
    Díaz-Montero CM; Naga O; Zidan AA; Salem ML; Pallin M; Parmigiani A; Walker G; Wieder E; Komanduri K; Cole DJ; Montero AJ; Lichtenheld MG
    Am J Cancer Res; 2011 Aug; 1(7):882-96. PubMed ID: 21915391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.
    Kosaka A; Ohkuri T; Ikeura M; Kohanbash G; Okada H
    Biochem Biophys Res Commun; 2015 Mar; 458(3):549-554. PubMed ID: 25677619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
    Hinrichs CS; Palmer DC; Rosenberg SA; Restifo NP
    J Immunother; 2005; 28(6):517-24. PubMed ID: 16224268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.
    Nelson MH; Bowers JS; Bailey SR; Diven MA; Fugle CW; Kaiser AD; Wrzesinski C; Liu B; Restifo NP; Paulos CM
    J Immunother Cancer; 2016; 4():6. PubMed ID: 26885368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
    Wang LX; Li R; Yang G; Lim M; O'Hara A; Chu Y; Fox BA; Restifo NP; Urba WJ; Hu HM
    Cancer Res; 2005 Nov; 65(22):10569-77. PubMed ID: 16288050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
    Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
    J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor.
    Hwang LN; Yu Z; Palmer DC; Restifo NP
    Cancer Res; 2006 Jan; 66(2):1132-8. PubMed ID: 16424050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cx43-Gap Junctions Accumulate at the Cytotoxic Immunological Synapse Enabling Cytotoxic T Lymphocyte Melanoma Cell Killing.
    Hofmann F; Navarrete M; Álvarez J; Guerrero I; Gleisner MA; Tittarelli A; Salazar-Onfray F
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
    Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
    Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
    Klebanoff CA; Finkelstein SE; Surman DR; Lichtman MK; Gattinoni L; Theoret MR; Grewal N; Spiess PJ; Antony PA; Palmer DC; Tagaya Y; Rosenberg SA; Waldmann TA; Restifo NP
    Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1969-74. PubMed ID: 14762166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.
    Shi LZ; Goswami S; Fu T; Guan B; Chen J; Xiong L; Zhang J; Ng Tang D; Zhang X; Vence L; Blando J; Allison JP; Collazo R; Gao J; Sharma P
    Cancer Immunol Res; 2019 Nov; 7(11):1803-1812. PubMed ID: 31466995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of CD8+ T cells in the tumor growth delay induced by Toxoplasma gondii excreted-secreted antigen in B16F10 mouse melanoma model].
    Jiao YM; Fang Q; Xia H; Wang XM; Tao ZY; Chen XZ; Shen JL
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2013 Apr; 31(2):95-8. PubMed ID: 24809186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
    Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
    Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
    Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
    J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.